- MediciNova ( NASDAQ: MNOV ) said on Wednesday that a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for its small molecule candidate MN-166 (ibudilast).
- Under the partnership with BARDA, the company will repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
- The contract was amended to extend the period of performance until March 2023.
- BARDA, a division of the U.S. Department of Health and Human Services will fund the proof-of-concept studies in preclinical models of chlorine gas-induced acute lung injury.
- The project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority.
- Last year in March, MediciNova jumps on BARDA partnership for Ibudilast development .
- Shares are up 2.75% after-hours.
For further details see:
MediciNova announces extension of BARDA contract for Ibudilast development